Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr1.85 DKK
Change Today +0.05 / 2.78%
Volume 852.5K
BIOPOR On Other Exchanges
Symbol
Exchange
Copenhagen
As of 8:55 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

bioporto a/s (BIOPOR) Snapshot

Open
kr1.80
Previous Close
kr1.80
Day High
kr1.87
Day Low
kr1.70
52 Week High
07/4/14 - kr2.90
52 Week Low
10/16/14 - kr1.35
Market Cap
218.1M
Average Volume 10 Days
204.7K
EPS TTM
kr-0.11
Shares Outstanding
117.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOPORTO A/S (BIOPOR)

Related News

No related news articles were found.

bioporto a/s (BIOPOR) Related Businessweek News

No Related Businessweek News Found

bioporto a/s (BIOPOR) Details

BioPorto A/S, an in-vitro diagnostics company, develops and markets diagnostic tests and antibodies for the healthcare professionals in clinical and research settings. Its products include neutrophil gelatinase-associated lipocalin (NGAL) Test for the diagnosis of acute kidney injury; and NGAL enzyme-linked immunosorbent assay (ELISA) kit for the in vitro determination of human NGAL in urine, plasma, serum, tissue extracts, or culture media. The company also provides activated protein C and protein C inhibitor complex (APC-PCI) ELISA kit that measures the APC-PCI in human plasma for the treatment of sepsis; and mannan-binding lectin (MBL) oligomer ELISA kit to determine oligomerized MBL in human serum or heparin plasma for the assessment of primary immunodeficiency. In addition, it markets various monoclonal antibodies under the AntibodyShop name, including antibodies for the research in the areas of NGAL; peptide hormones, including type-2 diabetes/obesity; immunology; and microbiology. The company was founded in 2000 and is based in Gentofte, Denmark.

24 Employees
Last Reported Date: 03/18/15
Founded in 2000

bioporto a/s (BIOPOR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioporto a/s (BIOPOR) Key Developments

BioPorto A/S Approves the Election of Jan Kuhlmann Andersen as a New Board Member

BioPorto A/S held its Annual General Meeting on April 10, 2015, the shareholders approved the election of Jan Kuhlmann Andersen as a new board member.

BioPorto A/S Reports Earnings Results for the Full Year Ended December 31, 2014

BioPorto A/S reported earnings results for the full year ended December 31, 2014. For the year, the company reported revenue of DKK 18.705 million compared to DKK 16.625 million a year ago. Negative EBIT was DKK 15.256 million compared to DKK 19.802 million a year ago. Loss before tax was DKK 15.097 million compared to DKK 21.873 million a year ago. Loss was DKK 12.926 million or DKK 0.11 per diluted share compared to DKK 21.873 million DKK 0.28 per diluted share a year ago. Cash flows used in operating activities was DKK 16.138 million compared to DKK 16.640 million a year ago. Purchase of operating equipment was of DKK 0.542 million compared to DKK 0.028 million a year ago.

BioPorto A/S Announces Executive Changes

Mr. Otto Rasmussen will step down as CFO of BioPorto A/S at January 31, 2015 to become Finance Director of Xellia Pharmaceuticals. Mrs. Birgitte Svendsen has been appointed interim CFO of BioPorto from February 1, 2015. Birgitte is a former accountant at Arthur Andersen and has previously also held positions as controller and financial director in companies like Novo Nordisk, Carat Danmark and Tiscali/World Online. Now, Birgitte is partner and CEO of Pecunia Consult. Going forward, the executive management at BioPorto A/S will be constituted by Peter Mørch Eriksen, CEO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOPOR:DC kr1.85 DKK +0.05

BIOPOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr316.00 DKK -1.50
Chimerix Inc $36.42 USD +1.08
Emergent Biosolutions Inc $31.08 USD +0.34
GlaxoSmithKline PLC 1,520 GBp +8.50
View Industry Companies
 

Industry Analysis

BIOPOR

Industry Average

Valuation BIOPOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOPORTO A/S, please visit www.bioporto.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.